These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22821644)

  • 21. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
    Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic.
    Kojima M; Ohashi M; Dohi Y; Kimura G
    J Hypertens; 2013 Jan; 31(1):186-91. PubMed ID: 23047595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
    Sanchez RA; Masnatta LD; Pesiney C; Fischer P; Ramirez AJ
    J Hypertens; 2008 Dec; 26(12):2393-8. PubMed ID: 19008718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice.
    Rong X; Li Y; Ebihara K; Zhao M; Aini W; Kusakabe T; Hirata M; Miyamoto L; Murray M; Nakao K
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1096-103. PubMed ID: 19770292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.
    Mori Y; Itoh Y; Tajima N
    Adv Ther; 2007; 24(1):146-53. PubMed ID: 17526471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.
    Nagel JM; Tietz AB; Göke B; Parhofer KG
    Metabolism; 2006 Sep; 55(9):1149-54. PubMed ID: 16919531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.
    Derosa G; Cicero AF; Bertone G; Piccinni MN; Fogari E; Ciccarelli L; Fogari R
    Clin Ther; 2004 Aug; 26(8):1228-36. PubMed ID: 15476904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function.
    Ono Y; Nakaya Y; Bando S; Soeki T; Ito S; Sata M
    Int Heart J; 2009 Jan; 50(1):73-83. PubMed ID: 19246848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
    Younis F; Kariv N; Nachman R; Zangen S; Rosenthal T
    Clin Exp Hypertens; 2007 Aug; 29(6):419-26. PubMed ID: 17729058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes.
    Kobayashi K; Ohno Y; Takenaka T; Ikeda N; Okada H; Kanno Y; Suzuki H
    Clin Exp Hypertens; 2011; 33(2):100-5. PubMed ID: 21269058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials.
    Takagi H; Umemoto T
    Int J Cardiol; 2012 Mar; 155(3):448-51. PubMed ID: 22192290
    [No Abstract]   [Full Text] [Related]  

  • 35. Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy.
    Hinoi T; Tomohiro Y; Kajiwara S; Matsuo S; Fujimoto Y; Yamamoto S; Shichijo T; Ono T
    Hypertens Res; 2008 Apr; 31(4):615-22. PubMed ID: 18633172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity.
    Komiya N; Hirose H; Kawabe H; Itoh H; Saito I
    J Atheroscler Thromb; 2009 Apr; 16(2):137-42. PubMed ID: 19403983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
    Hong SJ; Choi SC; Ahn CM; Park JH; Kim JS; Lim DS
    Heart; 2011 Sep; 97(17):1425-32. PubMed ID: 21700754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.
    Kamari Y; Harari A; Shaish A; Peleg E; Sharabi Y; Harats D; Grossman E
    Hypertens Res; 2008 Jan; 31(1):135-40. PubMed ID: 18360028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.
    Littlejohn TW; Majul CR; Olvera R; Seeber M; Kobe M; Guthrie R; Oigman W;
    Postgrad Med; 2009 Mar; 121(2):5-14. PubMed ID: 19332958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.